Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Comtusi Forte
- Development stage
- Unknown
- Lead developer
- Combiphar
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Comtusi Forte is an oral combination medication developed and marketed by Combiphar, containing the sedative antihistamine oxomemazine and the expectorant guaifenesin. Oxomemazine acts as a competitive antagonist at histamine H1 receptors and muscarinic M1 receptors, reducing allergic symptoms and suppressing the cough reflex. Guaifenesin acts as an expectorant by increasing the volume and reducing the viscosity of respiratory tract secretions, facilitating mucus clearance. Comtusi Forte is approved in Indonesia for the symptomatic relief of allergy-related coughs and coughs with phlegm.
- Brand names
- Comtusi Forte
- Other names
- Comtusi
02
Targets
HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)
Beyond the preview
Go deeper on Comtusi Forte.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Comtusi Forte.